Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals

INTRODUCTION: Declarations of conflicts of interest have received considerable scrutiny in recent years. AIM: To determine if the leading gastroenterology journals had a formal conflict of interest disclosure policy and the extent to which this policy was followed by reporting of funding sources and potential conflicts of interests of the authors and editors of published studies. METHODS: We examined original articles and editorials in 12 leading journals (determined by impact factor) devoted to gastroenterology and hepatology. We examined the editorial policy of the journal (if available) on the Web site of the journal or in print versions of the journal and contacted the journal for further information on editorial policies. RESULTS: A total of 1,114 original articles and 154 editorials were evaluated from 12 journals. The source of funding for a study was disclosed in 19-99% of the articles examined with only one journal reporting the funding source (or absence of funding) in over 90% of articles studied. A potential conflict of interest was present in 0-13% of original articles and 0-33% of editorials. Only 2 of 12 (17%) journals publicly disclosed the conflicts of interest of the editors to the reader and only 3 (25%) had a formal method for handling editors' conflicts of interest. CONCLUSIONS: Editors of gastroenterology and hepatology journals have been slow to implement guidelines for the disclosure of their own conflicts of interest. Disclosure of funding sources and conflicts of interest of authors is variable despite the presence of conflict of interest policies at most journals.     

商陆多糖Ⅰ联合白细胞介素2对小鼠脾细胞杀瘤活性的影响

商陆多糖Ⅰ(PAP-I),0.3～3μg·ml^-1和小鼠脾细胞培养3～5d可显著增强其杀伤P815肿瘤细胞活性及IL-2(250～500IU·ml^-1)诱导的LAK细胞活性,最适浓度为1μg·ml^-1。PAP-I及IL-2和脾细胞培养的上清液对P815肿瘤细胞无细胞毒作用,但能增强脾细胞及LAK细胞杀瘤活性。PAP-I,5,10及50mg·kg-1,ip可增强脾细胞杀伤P₈₁₅和L₉₂₉细胞的活性及IL-2诱导的LAK细胞活性。     

Ramipril and methyldopa compared in patients with mild to moderate hypertension

Twenty-seven patients with mild to moderate essential hypertension were randomly assigned to receive 5 mg of ramipril once daily or 250 mg of methyldopa twice daily for eight weeks. Similar reductions in diastolic blood pressure and heart rate were noted in the two treatment groups during treatment. Perhaps because of the limited number of patients, no between-group differences in the results of a measure of quality of life were found, but on overall assessments of treatment outcome by patients and the investigator, slightly better outcome was apparent in the ramipril-treated patients. No side effects or clinically significant changes in laboratory test results were reported. It is concluded that ramipril is a safe and effective agent in mild to moderate hypertension when administered as a single daily dose.     

Cloning, functional activities and in vivo tissue distribution of rat NKR-P1+ TCR alpha beta + cells

We have successfully cloned nine NKR-P1+ TCR alpha beta + cells from PVG rat spleens, utilizing murine macrophage inflammatory protein-1 alpha (MIP-1 alpha) and IL-2. These clones are either double negative (DN, CD4-CD8-), which included clones 3.31, 3.71, 4.19, 4.59 and 4.65, or single positive (SP, CD4+CD8-), which included clones 1.64, 3.8, 3.76 and 3.78. No CD8+ clone was recovered. All nine clones are restricted in terms of their expression of the V beta antigens, since they express V beta 8.2 but not V beta 8.5, V beta 10 or V beta 16. These clones are agranular and they fall to generate NK or LAK activity upon incubation with IL-2, IL-12 or their combination. On the basis of their production of intracellular cytokines they can be divided into three categories: (I) SP clones (1.64, 3.8, 3.76 and 3.78) do not produce IL-2 or IL-4, but produce IFN-gamma and IL-12, and they vary in their production of IL-1, RANTES or tumor necrosis factor (TNF)-alpha; (II) DN clones 4.59 and 4.65 produce IL-1 alpha and IFN-gamma only, and fall to produce other cytokines; and (III) DN clones 3.31, 3.71 and 4.19 produce IL-1 alpha, IL-1 beta, IL-2, IL-12, IFN-gamma, RANTES and TNF-alpha. From all the clones examined only DN clones 3.31 and to a lesser degree 4.19 produce IL-4. In vivo tissue localization of clones 3.8, 3.31 and 4.59 shows that these cells distribute into the liver and bone marrow 24 h post i.v. administration. Their accumulation in the liver and bone marrow along with their ability to secrete various cytokines suggest that these cells may influence the generation, differentiation or apoptosis of immune or hematopoietic cells.      

Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection

OBJECTIVE: There is uncertainty about the best method of testing patients for Helicobacter pylori (H. pylori) infection while they are taking proton pump inhibitors. The aim of this study was to determine: (i) if the decreased sensitivity of the urea breath test during proton pump inhibitor is corrected by different techniques for breath testing and (ii) if the sensitivity of stool test is decreased with the administration of proton pump inhibitors. METHODS: Prospective randomized single-blind study was performed in a tertiary care university hospital. Out of 72 H. pylori infected patients endoscoped for upper abdominal symptoms 48 were randomized to proton pump inhibitors (omeprazole 20 mg each day or esomeprazole 40 mg each day) and 24 to antacid (aluminum hydroxide 800 mg each day) for 14 days. Several breath tests (standard 75 mg (13)C-UBT with citric acid, with orange juice, a tablet breath test with 100 and 50 mg of (13)C), and a stool test were carried out. Baseline samples were collected before and after treatment. RESULTS: The baseline sensitivity for all breath tests was 100% in both groups; for stool test it was 97.8% (95% CI: 88.7-96.6) and 90% (95% CI: 69.9-97.2) in the proton pump inhibitor and antacid group, respectively. After treatment, the sensitivity of tests was significantly low (UBTs range: 77.1%-85.4%; stool test: 83%; 95% CI: 63.9-91.1), while it was unchanged in the antacid group. CONCLUSIONS: False negative breath and stool tests are equally common in patients taking proton pump inhibitors. Antacids do not impair the sensitivity of the breath tests or the stool test.     

Correction for arterial-tissue delay and dispersion in absolute quantitative cerebral perfusion DSC MR imaging

The singular value decomposition deconvolution of cerebral tissue concentration-time curves with the arterial input function is commonly used in dynamic susceptibility contrast cerebral perfusion MR imaging. However, it is sensitive to the time discrepancy between the arrival of the bolus in the tissue concentration-time curve and the arterial input function signal. This normally causes inaccuracy in the quantitative perfusion maps due to delay and dispersion effects. A comprehensive correction algorithm has been achieved through slice-dependent time-shifting of the arterial input function, and a delay-dependent dispersion correction model. The correction algorithm was tested in 11 healthy subjects and three ischemic stroke patients scanned with a quantitative perfusion pulse sequence at 1.5 T. A validation study was performed on five patients with confirmed cerebrovascular occlusive disease scanned with MRI and positron emission tomography at 3.0 T. A significant effect (P < 0.05) was reported on the quantitative cerebral blood flow and mean transit time measurements (up to 50%). There was no statistically significant effect on the quantitative cerebral blood volume values. The in vivo results were in agreement with the simulation results, as well as previous literature. This minimizes the bias in patient diagnosis due to the existing errors and artifacts in dynamic susceptibility contrast imaging.